Activated ERK1/2 and phosphorylated oestrogen receptor α are associated with improved breast cancer survival in women treated with tamoxifen
The aim of this study was to investigate the expression of activated (phosphorylated) ERK1/2, oestrogen receptor α phosphorylated at S118 (ERα S118), and HER2 in primary breast cancer, and to make correlations with the outcome of tamoxifen therapy. We performed immunohistochemical analysis to determ...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer (1990) 2006-05, Vol.42 (8), p.1104-1112 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1112 |
|---|---|
| container_issue | 8 |
| container_start_page | 1104 |
| container_title | European journal of cancer (1990) |
| container_volume | 42 |
| creator | Bergqvist, Jenny Elmberger, Goran Ohd, John Linderholm, Barbro Bjohle, Judith Hellborg, Henrik Nordgren, Hans Borg, Anna-Lena Skoog, Lambert Bergh, Jonas |
| description | The aim of this study was to investigate the expression of activated (phosphorylated) ERK1/2, oestrogen receptor α phosphorylated at S118 (ERα
S118), and HER2 in primary breast cancer, and to make correlations with the outcome of tamoxifen therapy. We performed immunohistochemical analysis to determine the expression of HER2, ERα
S118, and activated ERK1/2 in tumours obtained from 279 women with primary breast cancer. HER2 status was also estimated by fluorescence in situ hybridisation. We identified 108 women with ERα-positive tumours who had received adjuvant tamoxifen. Activated ERK1/2 (pERK1/2) and ERα
S118 were found to be associated with each other and with other factors correlated with good prognosis. HER2 was inversely associated with pERK1/2. Positive staining for pERK1/2 (particularly intense staining) indicated better relapse-free survival (
P
=
0.05) and a trend towards better breast cancer-corrected survival in women treated with tamoxifen. To conclude, this study shows that activated ERK1/2 and ERα
S118 are associated with improved survival. The poorer outcome in HER2-positive women who receive adjuvant tamoxifen cannot be explained by the crosstalk between HER2 and ERα
S118 via activated ERK1/2 alone. |
| doi_str_mv | 10.1016/j.ejca.2006.01.028 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_576141</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0959804906001559</els_id><sourcerecordid>67974455</sourcerecordid><originalsourceid>FETCH-LOGICAL-c476t-41c94d42d6debdb491e3caf74ff4d9cca4fd4edae979d2022466f7a27678ea633</originalsourceid><addsrcrecordid>eNp9ks1u1DAUhSMEotPCC7BAXrFBSW3HsWOJzaiUH1EJCQFby7FvWg-TONjODH2IPgwvwjPh6Qztqiws_33nWL73FMULgiuCCT9dVbAyuqIY8wqTCtP2UbEgrZAlbhv6uFhg2ciyxUweFccxrjDGomX4aXFEOMd1zfiiuFma5DY6gUXnXz6RU4r0aNF05WMe4Xp9e-MhpuAvYUQBDEzJB_TnN9IBkI7RG3cLbV26Qm6Ygt_kXRdAx4SMHg0EFOewya-skRvR1g_ZKOX7O1XSg__lehifFU96vY7w_DCfFN_enX89-1BefH7_8Wx5URomeCoZMZJZRi230NmOSQK10b1gfc-sNEaz3jKwGqSQlmJKGee90FRw0YLmdX1SlHvfuIVp7tQU3KDDtfLaqcPRj7wC1QhOGMm8eJDPH7b3on9CIhkXUmTl6weVb933pfLhUs2zIgTXPNOv9nQ2_TnnqqvBRQPrtR7Bz1HtLBlrmgzSPWiCjzFAf2dMsNqFQ63ULhxqFw6FicrhyKKXB_e5G8DeSw5pyMCbPQC59hsHQUXjIHfQutz4pKx3__P_C6u20WE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67974455</pqid></control><display><type>article</type><title>Activated ERK1/2 and phosphorylated oestrogen receptor α are associated with improved breast cancer survival in women treated with tamoxifen</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Bergqvist, Jenny ; Elmberger, Goran ; Ohd, John ; Linderholm, Barbro ; Bjohle, Judith ; Hellborg, Henrik ; Nordgren, Hans ; Borg, Anna-Lena ; Skoog, Lambert ; Bergh, Jonas</creator><creatorcontrib>Bergqvist, Jenny ; Elmberger, Goran ; Ohd, John ; Linderholm, Barbro ; Bjohle, Judith ; Hellborg, Henrik ; Nordgren, Hans ; Borg, Anna-Lena ; Skoog, Lambert ; Bergh, Jonas</creatorcontrib><description>The aim of this study was to investigate the expression of activated (phosphorylated) ERK1/2, oestrogen receptor α phosphorylated at S118 (ERα
S118), and HER2 in primary breast cancer, and to make correlations with the outcome of tamoxifen therapy. We performed immunohistochemical analysis to determine the expression of HER2, ERα
S118, and activated ERK1/2 in tumours obtained from 279 women with primary breast cancer. HER2 status was also estimated by fluorescence in situ hybridisation. We identified 108 women with ERα-positive tumours who had received adjuvant tamoxifen. Activated ERK1/2 (pERK1/2) and ERα
S118 were found to be associated with each other and with other factors correlated with good prognosis. HER2 was inversely associated with pERK1/2. Positive staining for pERK1/2 (particularly intense staining) indicated better relapse-free survival (
P
=
0.05) and a trend towards better breast cancer-corrected survival in women treated with tamoxifen. To conclude, this study shows that activated ERK1/2 and ERα
S118 are associated with improved survival. The poorer outcome in HER2-positive women who receive adjuvant tamoxifen cannot be explained by the crosstalk between HER2 and ERα
S118 via activated ERK1/2 alone.</description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/j.ejca.2006.01.028</identifier><identifier>PMID: 16603346</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adult ; Aged ; Antineoplastic Agents, Hormonal - therapeutic use ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - mortality ; Breast Neoplasms/drug therapy/mortality ; c-erbB-2 ; ERK1/2 ; Estrogen Receptor alpha - metabolism ; Female ; HER-2 ; Humans ; In Situ Hybridization, Fluorescence ; Medicin och hälsovetenskap ; Middle Aged ; Mitogen-Activated Protein Kinase 3 - metabolism ; Phosphorylated ERα ; Phosphorylation ; Receptor, ErbB-2 - metabolism ; Survival Analysis ; Tamoxifen ; Tamoxifen - therapeutic use</subject><ispartof>European journal of cancer (1990), 2006-05, Vol.42 (8), p.1104-1112</ispartof><rights>2006 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c476t-41c94d42d6debdb491e3caf74ff4d9cca4fd4edae979d2022466f7a27678ea633</citedby><cites>FETCH-LOGICAL-c476t-41c94d42d6debdb491e3caf74ff4d9cca4fd4edae979d2022466f7a27678ea633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejca.2006.01.028$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16603346$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-11036$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:1946797$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Bergqvist, Jenny</creatorcontrib><creatorcontrib>Elmberger, Goran</creatorcontrib><creatorcontrib>Ohd, John</creatorcontrib><creatorcontrib>Linderholm, Barbro</creatorcontrib><creatorcontrib>Bjohle, Judith</creatorcontrib><creatorcontrib>Hellborg, Henrik</creatorcontrib><creatorcontrib>Nordgren, Hans</creatorcontrib><creatorcontrib>Borg, Anna-Lena</creatorcontrib><creatorcontrib>Skoog, Lambert</creatorcontrib><creatorcontrib>Bergh, Jonas</creatorcontrib><title>Activated ERK1/2 and phosphorylated oestrogen receptor α are associated with improved breast cancer survival in women treated with tamoxifen</title><title>European journal of cancer (1990)</title><addtitle>Eur J Cancer</addtitle><description>The aim of this study was to investigate the expression of activated (phosphorylated) ERK1/2, oestrogen receptor α phosphorylated at S118 (ERα
S118), and HER2 in primary breast cancer, and to make correlations with the outcome of tamoxifen therapy. We performed immunohistochemical analysis to determine the expression of HER2, ERα
S118, and activated ERK1/2 in tumours obtained from 279 women with primary breast cancer. HER2 status was also estimated by fluorescence in situ hybridisation. We identified 108 women with ERα-positive tumours who had received adjuvant tamoxifen. Activated ERK1/2 (pERK1/2) and ERα
S118 were found to be associated with each other and with other factors correlated with good prognosis. HER2 was inversely associated with pERK1/2. Positive staining for pERK1/2 (particularly intense staining) indicated better relapse-free survival (
P
=
0.05) and a trend towards better breast cancer-corrected survival in women treated with tamoxifen. To conclude, this study shows that activated ERK1/2 and ERα
S118 are associated with improved survival. The poorer outcome in HER2-positive women who receive adjuvant tamoxifen cannot be explained by the crosstalk between HER2 and ERα
S118 via activated ERK1/2 alone.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents, Hormonal - therapeutic use</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms/drug therapy/mortality</subject><subject>c-erbB-2</subject><subject>ERK1/2</subject><subject>Estrogen Receptor alpha - metabolism</subject><subject>Female</subject><subject>HER-2</subject><subject>Humans</subject><subject>In Situ Hybridization, Fluorescence</subject><subject>Medicin och hälsovetenskap</subject><subject>Middle Aged</subject><subject>Mitogen-Activated Protein Kinase 3 - metabolism</subject><subject>Phosphorylated ERα</subject><subject>Phosphorylation</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Survival Analysis</subject><subject>Tamoxifen</subject><subject>Tamoxifen - therapeutic use</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9ks1u1DAUhSMEotPCC7BAXrFBSW3HsWOJzaiUH1EJCQFby7FvWg-TONjODH2IPgwvwjPh6Qztqiws_33nWL73FMULgiuCCT9dVbAyuqIY8wqTCtP2UbEgrZAlbhv6uFhg2ciyxUweFccxrjDGomX4aXFEOMd1zfiiuFma5DY6gUXnXz6RU4r0aNF05WMe4Xp9e-MhpuAvYUQBDEzJB_TnN9IBkI7RG3cLbV26Qm6Ygt_kXRdAx4SMHg0EFOewya-skRvR1g_ZKOX7O1XSg__lehifFU96vY7w_DCfFN_enX89-1BefH7_8Wx5URomeCoZMZJZRi230NmOSQK10b1gfc-sNEaz3jKwGqSQlmJKGee90FRw0YLmdX1SlHvfuIVp7tQU3KDDtfLaqcPRj7wC1QhOGMm8eJDPH7b3on9CIhkXUmTl6weVb933pfLhUs2zIgTXPNOv9nQ2_TnnqqvBRQPrtR7Bz1HtLBlrmgzSPWiCjzFAf2dMsNqFQ63ULhxqFw6FicrhyKKXB_e5G8DeSw5pyMCbPQC59hsHQUXjIHfQutz4pKx3__P_C6u20WE</recordid><startdate>20060501</startdate><enddate>20060501</enddate><creator>Bergqvist, Jenny</creator><creator>Elmberger, Goran</creator><creator>Ohd, John</creator><creator>Linderholm, Barbro</creator><creator>Bjohle, Judith</creator><creator>Hellborg, Henrik</creator><creator>Nordgren, Hans</creator><creator>Borg, Anna-Lena</creator><creator>Skoog, Lambert</creator><creator>Bergh, Jonas</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>DF2</scope></search><sort><creationdate>20060501</creationdate><title>Activated ERK1/2 and phosphorylated oestrogen receptor α are associated with improved breast cancer survival in women treated with tamoxifen</title><author>Bergqvist, Jenny ; Elmberger, Goran ; Ohd, John ; Linderholm, Barbro ; Bjohle, Judith ; Hellborg, Henrik ; Nordgren, Hans ; Borg, Anna-Lena ; Skoog, Lambert ; Bergh, Jonas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c476t-41c94d42d6debdb491e3caf74ff4d9cca4fd4edae979d2022466f7a27678ea633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents, Hormonal - therapeutic use</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms/drug therapy/mortality</topic><topic>c-erbB-2</topic><topic>ERK1/2</topic><topic>Estrogen Receptor alpha - metabolism</topic><topic>Female</topic><topic>HER-2</topic><topic>Humans</topic><topic>In Situ Hybridization, Fluorescence</topic><topic>Medicin och hälsovetenskap</topic><topic>Middle Aged</topic><topic>Mitogen-Activated Protein Kinase 3 - metabolism</topic><topic>Phosphorylated ERα</topic><topic>Phosphorylation</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Survival Analysis</topic><topic>Tamoxifen</topic><topic>Tamoxifen - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bergqvist, Jenny</creatorcontrib><creatorcontrib>Elmberger, Goran</creatorcontrib><creatorcontrib>Ohd, John</creatorcontrib><creatorcontrib>Linderholm, Barbro</creatorcontrib><creatorcontrib>Bjohle, Judith</creatorcontrib><creatorcontrib>Hellborg, Henrik</creatorcontrib><creatorcontrib>Nordgren, Hans</creatorcontrib><creatorcontrib>Borg, Anna-Lena</creatorcontrib><creatorcontrib>Skoog, Lambert</creatorcontrib><creatorcontrib>Bergh, Jonas</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Uppsala universitet</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bergqvist, Jenny</au><au>Elmberger, Goran</au><au>Ohd, John</au><au>Linderholm, Barbro</au><au>Bjohle, Judith</au><au>Hellborg, Henrik</au><au>Nordgren, Hans</au><au>Borg, Anna-Lena</au><au>Skoog, Lambert</au><au>Bergh, Jonas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Activated ERK1/2 and phosphorylated oestrogen receptor α are associated with improved breast cancer survival in women treated with tamoxifen</atitle><jtitle>European journal of cancer (1990)</jtitle><addtitle>Eur J Cancer</addtitle><date>2006-05-01</date><risdate>2006</risdate><volume>42</volume><issue>8</issue><spage>1104</spage><epage>1112</epage><pages>1104-1112</pages><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract>The aim of this study was to investigate the expression of activated (phosphorylated) ERK1/2, oestrogen receptor α phosphorylated at S118 (ERα
S118), and HER2 in primary breast cancer, and to make correlations with the outcome of tamoxifen therapy. We performed immunohistochemical analysis to determine the expression of HER2, ERα
S118, and activated ERK1/2 in tumours obtained from 279 women with primary breast cancer. HER2 status was also estimated by fluorescence in situ hybridisation. We identified 108 women with ERα-positive tumours who had received adjuvant tamoxifen. Activated ERK1/2 (pERK1/2) and ERα
S118 were found to be associated with each other and with other factors correlated with good prognosis. HER2 was inversely associated with pERK1/2. Positive staining for pERK1/2 (particularly intense staining) indicated better relapse-free survival (
P
=
0.05) and a trend towards better breast cancer-corrected survival in women treated with tamoxifen. To conclude, this study shows that activated ERK1/2 and ERα
S118 are associated with improved survival. The poorer outcome in HER2-positive women who receive adjuvant tamoxifen cannot be explained by the crosstalk between HER2 and ERα
S118 via activated ERK1/2 alone.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>16603346</pmid><doi>10.1016/j.ejca.2006.01.028</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-8049 |
| ispartof | European journal of cancer (1990), 2006-05, Vol.42 (8), p.1104-1112 |
| issn | 0959-8049 1879-0852 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_576141 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adult Aged Antineoplastic Agents, Hormonal - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - mortality Breast Neoplasms/drug therapy/mortality c-erbB-2 ERK1/2 Estrogen Receptor alpha - metabolism Female HER-2 Humans In Situ Hybridization, Fluorescence Medicin och hälsovetenskap Middle Aged Mitogen-Activated Protein Kinase 3 - metabolism Phosphorylated ERα Phosphorylation Receptor, ErbB-2 - metabolism Survival Analysis Tamoxifen Tamoxifen - therapeutic use |
| title | Activated ERK1/2 and phosphorylated oestrogen receptor α are associated with improved breast cancer survival in women treated with tamoxifen |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T00%3A14%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Activated%20ERK1/2%20and%20phosphorylated%20oestrogen%20receptor%20%CE%B1%20are%20associated%20with%20improved%20breast%20cancer%20survival%20in%20women%20treated%20with%20tamoxifen&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=Bergqvist,%20Jenny&rft.date=2006-05-01&rft.volume=42&rft.issue=8&rft.spage=1104&rft.epage=1112&rft.pages=1104-1112&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/j.ejca.2006.01.028&rft_dat=%3Cproquest_swepu%3E67974455%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67974455&rft_id=info:pmid/16603346&rft_els_id=S0959804906001559&rfr_iscdi=true |